Turning Point Therapeutics, Inc.
TPTX · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $3,740,140 | $1,332,069 | $2,361,080 | $3,283,402 |
| - Cash | $290,147 | $309,532 | $427,879 | $404,203 |
| + Debt | $4,937 | $5,834 | $5,579 | $6,390 |
| Enterprise Value | $3,454,930 | $1,028,371 | $1,938,780 | $2,885,589 |
| Revenue | $119 | $429 | $25 | $460 |
| % Growth | -72.3% | 1,602% | -94.5% | – |
| Gross Profit | $119 | $429 | $25 | $460 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$121,772 | -$73,191 | -$77,175 | -$65,443 |
| % Margin | -102,329.4% | -17,060.8% | -306,189.2% | -14,226.7% |
| Net Income | -$123,088 | -$74,445 | -$78,449 | -$66,325 |
| % Margin | -103,435.3% | -17,353.1% | -311,243.8% | -14,418.5% |
| EPS Diluted | -2.48 | -1.5 | -1.58 | -1.34 |
| % Growth | -65.3% | 5.1% | -17.9% | – |
| Operating Cash Flow | -$105,298 | -$58,331 | -$54,151 | -$41,665 |
| Capital Expenditures | -$1,527 | -$447 | -$387 | -$1,166 |
| Free Cash Flow | -$106,825 | -$58,778 | -$54,538 | -$42,831 |